<span item_type="fundamental" item_id="6dfc5ae70f8d766ff86efe506eddca33" counter_id="ST/US/INO" env="prod"></span><span item_type="announcement" item_id="648011953533686529" env="prod"></span><p>Revenue: As of FY2026 Q1, the actual value is USD 0.</p><p>EPS: As of FY2026 Q1, the actual value is USD -0.28, beating the estimate of USD -0.35.</p><p>EBIT: As of FY2026 Q1, the actual value is USD -22.39 M.</p><p></p><h4>Revenue</h4><ul><li>Revenue from collaborative arrangement was $0 for the three months ended March 31, 2026, compared to $65,343 for the same period in 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1055726/000105572626000019/ino-33126x8kex991.htm"></span></li></ul><h4>Operating Expenses</h4><ul><li>Research and Development (R&amp;D) Expenses decreased to $14,070,107 for the three months ended March 31, 2026, from $16,090,902 for the same period in 2025, primarily due to lower employee and consultant compensation, reduced engineering outside services, and lower expensed inventory.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1055726/000105572626000019/ino-33126x8kex991.htm"></span></li><li>General and Administrative (G&amp;A) Expenses decreased to $7,879,886 for the three months ended March 31, 2026, from $9,024,970 for the same period in 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1055726/000105572626000019/ino-33126x8kex991.htm"></span></li><li>Total Operating Expenses decreased to $21,949,993 for the three months ended March 31, 2026, from $25,115,872 for the same period in 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1055726/000105572626000019/ino-33126x8kex991.htm"></span></li></ul><h4>Profitability</h4><ul><li>Loss from Operations was - $21,949,993 for the three months ended March 31, 2026, compared to - $25,050,529 for the same period in 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1055726/000105572626000019/ino-33126x8kex991.htm"></span></li><li>Net Loss was - $19,682,798 for the three months ended March 31, 2026, compared to - $19,694,697 for the same period in 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1055726/000105572626000019/ino-33126x8kex991.htm"></span></li><li>Net Loss per Share (Basic and Diluted) was - $0.28 for the three months ended March 31, 2026, compared to - $0.51 for the same period in 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1055726/000105572626000019/ino-33126x8kex991.htm"></span></li></ul><h4>Cash and Investments</h4><ul><li>Cash, Cash Equivalents and Short-term Investments totaled $37.7 million as of March 31, 2026 (excluding net proceeds from the April 2026 offering of $16.0 million), a decrease from $58.5 million as of December 31, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1055726/000105572626000019/ino-33126x8kex991.htm"></span></li></ul><h4>Balance Sheet Highlights</h4><ul><li>Total Current Assets were $39,439,605 as of March 31, 2026, down from $61,123,346 as of December 31, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1055726/000105572626000019/ino-33126x8kex991.htm"></span></li><li>Total Assets were $49,777,142 as of March 31, 2026, compared to $74,310,035 as of December 31, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1055726/000105572626000019/ino-33126x8kex991.htm"></span></li><li>Total Current Liabilities were $37,923,025 as of March 31, 2026, compared to $43,668,555 as of December 31, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1055726/000105572626000019/ino-33126x8kex991.htm"></span></li><li>Total Liabilities were $43,709,260 as of March 31, 2026, compared to $50,213,759 as of December 31, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1055726/000105572626000019/ino-33126x8kex991.htm"></span></li><li>Total Stockholders’ Equity was $6,067,882 as of March 31, 2026, compared to $24,096,276 as of December 31, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1055726/000105572626000019/ino-33126x8kex991.htm"></span></li></ul><h4>Operational Metrics / Business Highlights</h4><ul><li>The Biologics License Application (BLA) for INO-3107 is under active review by the U.S. Food and Drug Administration (FDA) with a target Prescription Drug User Fee Act (PDUFA) date of October 30, 2026.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1055726/000105572626000019/ino-33126x8kex991.htm"></span></li><li>Inovio Pharmaceuticals, Inc. is advancing commercial readiness plans for INO-3107 in anticipation of a potential approval in 2026 and plans to commercialize it in the U.S. with a contract sales organization.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1055726/000105572626000019/ino-33126x8kex991.htm"></span></li><li>A clinical trial collaboration and supply agreement was announced with Akeso Inc. to evaluate INO-5412 in combination with cadonilimab for glioblastoma (GBM).<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1055726/000105572626000019/ino-33126x8kex991.htm"></span></li><li>Inovio Pharmaceuticals, Inc. strengthened its balance sheet through an underwritten public equity offering in April 2026, generating approximately $16.0 million in net proceeds.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1055726/000105572626000019/ino-33126x8kex991.htm"></span></li></ul><h4>Outlook / Guidance</h4><p>Inovio Pharmaceuticals, Inc. estimates that its current cash, cash equivalents, and short-term investments will support operations into the first quarter of 2027, extending beyond the target PDUFA date for INO-3107.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1055726/000105572626000019/ino-33126x8kex991.htm"></span> This projection includes the $16.0 million net proceeds from the April 2026 public offering and an estimated operational net cash burn of approximately $18 million for the second quarter of 2026.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1055726/000105572626000019/ino-33126x8kex991.htm"></span> These cash runway projections do not account for any potential future capital-raising activities.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1055726/000105572626000019/ino-33126x8kex991.htm"></span></p>

Inovio Pharma | 8-K: FY2026 Q1 Revenue: USD 0